Reviews Open access

A systematic literature review of existing tools used to assess medication adherence in connective tissue diseases: the state of the art for the future development of co-designed measurement tools

Authors

Published
22 November 2021
Section
Reviews
DOI
10.4081/reumatismo.2021.1418

Abstract

Lack of medication adherence is frequent in chronic connective tissue diseases and is associated with poorer health outcomes, low quality of life and economic loss. This research is based on a systematic literature search and aims to identify the surveys and tools used for the assessment of medication adherence in patients with connective tissue diseases (CTDs) and in particular the tools co-designed with patients. A systematic literature review was performed in PubMed and Embase databases searching for studies concerning the application of surveys or tools designed for medication adherence assessment. A specific analysis was also performed to identify which of these existing tools were developed in co-design with patients affected by CTDs. 1958 references were identified, and 31 studies were finally included. Systemic lupus erythematosus was the most investigated disease, followed by the Behçet’s disease. The tools used to assess adherence in CTDs were, in most cases, valid and useful. However, the results showed a certain degree of heterogeneity among the studies and the medication adherence assessment and measurement tools adopted, which were mostly based on selfreported questionnaire. No co-designed tools with patients were found. Low- and non-adherence were explored in some CTDs with valid and useful tools, while other CTDs still need to be assessed. Therefore, more efforts should be made to better understand the specific reasons for the low- and non-adherence in CTDs patients.

Keywords

References

  1. Sabaté E, World Health Organization. Adherence to long-term therapies: evidence for action. World Health Organization; 2003, pp. 194. Available from: https://apps.who.int/medicinedocs/en/d/Js4883e/
  2. Coulter A, Entwistle VA, Eccles A, et al. Personalised care planning for adults with chronic or long-term health conditions. Cochrane Database Syst Rev. 2015; (3): CD010523. DOI: https://doi.org/10.1002/14651858.CD010523.pub2
  3. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008; (2): CD000011. DOI: https://doi.org/10.1002/14651858.CD000011.pub3
  4. Golay A. Pharmacoeconomic aspects of poor adherence: can better adherence reduce healthcare costs? J Med Econ. 2011; 14: 594-608. DOI: https://doi.org/10.3111/13696998.2011.597808
  5. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol. JAMA 2006; 296: 2563. DOI: https://doi.org/10.1001/jama.296.21.joc60162
  6. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011; 86: 304-14. DOI: https://doi.org/10.4065/mcp.2010.0575
  7. Lam WY, Fresco P. Medication adherence measures: an overview. BioMed Res Int. 2015; 2015: 217047. DOI: https://doi.org/10.1155/2015/217047
  8. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv. 2007; 58: 1187-92. DOI: https://doi.org/10.1176/ps.2007.58.9.1187
  9. Lavsa SM, Holzworth A, Ansani NT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc. 2011; 51: 90-4. DOI: https://doi.org/10.1331/JAPhA.2011.09154
  10. Nguyen T-M-U, Caze A La, Cottrell N. What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol. 2014; 77: 427-45. DOI: https://doi.org/10.1111/bcp.12194
  11. Sanders EB-N, Stappers PJ. Co-creation and the new landscapes of design. CoDesign 2008; 4: 5-18. DOI: https://doi.org/10.1080/15710880701875068
  12. Luxford K, Safran DG, Delbanco T. Promoting patient-centered care: a qualitative study of facilitators and barriers in healthcare organizations with a reputation for improving the patient experience. Int J Qual Heal Care. 2011; 23: 510-5. DOI: https://doi.org/10.1093/intqhc/mzr024
  13. Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open. 2013; 3(1). DOI: https://doi.org/10.1136/bmjopen-2012-001570
  14. Slattery P, Saeri AK, Bragge P. Research co-design in health: a rapid overview of reviews. Heal Res Policy Syst. 2020; 18: 17. DOI: https://doi.org/10.1186/s12961-020-0528-9
  15. Anghel L-A, Farcaş AM, Oprean RN. Medication adherence and persistence in patients with autoimmune rheumatic diseases: A narrative review. Patient Prefer Adherence. 2018; 12: 1151-66. DOI: https://doi.org/10.2147/PPA.S165101
  16. Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013; 27: 329-40. DOI: https://doi.org/10.1016/j.berh.2013.07.001
  17. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6: e1000100. DOI: https://doi.org/10.1371/journal.pmed.1000100
  18. Du X, Chen H, Zhuang Y, et al. Medication adherence in chinese patients with systemic lupus erythematosus. J Clin Rheumatol. 2020; 26: 94-8. DOI: https://doi.org/10.1097/RHU.0000000000000952
  19. Hachulla E, Gouellec N Le, Launay D, et al. Adherence to hydroxychloroquine in patients with systemic lupus: contrasting results and weak correlation between assessment tools. Jt Bone Spine 2020 [Epub ahead of print]. DOI: https://doi.org/10.1016/j.jbspin.2020.04.017
  20. Harry O, Crosby LE, Mara C, et al. Feasibility and acceptability of an innovative adherence intervention for young adults with childhood-onset systemic lupus erythematosus. Pediatr Rheumatol 2020; 18: 36. DOI: https://doi.org/10.1186/s12969-020-00430-z
  21. Ali AY, Abdelaziz TS, Essameldin M. The prevalence and causes non-adherence to immunosuppressive medications in patients with Lupus nephritis flares. Curr Rheumatol Rev 2019; 15.
  22. Brijs J, Arat S, Westhovens R, et al. Treatment adherence in systemic sclerosis: a cross-sectional study. Musculoskeletal Care. 2019; 17: 44-53. DOI: https://doi.org/10.1002/msc.1363
  23. Clowse MEB, Eudy AM, Revels J, et al. Provider perceptions on the management of lupus during pregnancy: barriers to improved care. Lupus. 2019; 28: 86-93. DOI: https://doi.org/10.1177/0961203318815594
  24. Amalia R, Sasongko H, Kundarto W, Niruri R. The analysis of the factors affecting medication adherence in patient with SLE (systemic lupus erythematosus) at Yayasan Tittari Griya Kupu solo. Indian J Public Heal Res Dev. 2019; 10: 672-6. DOI: https://doi.org/10.5958/0976-5506.2019.00580.1
  25. Sun K, Eudy AM, Rogers JL, et al. 197 Racial disparities in lupus medication adherence. Lupus Sci Med. 2019; 6: A147-8. DOI: https://doi.org/10.1136/lupus-2019-lsm.197
  26. Wallace DJ, Tse K, Hanrahan L, et al. Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: Survey results from 3127 patients with SLE conducted by the Lupus Foundation of America. Lupus Sci Med. 2019; 6(1). DOI: https://doi.org/10.1136/lupus-2019-000317
  27. Zayed HS, Medhat BM, Seif EM. Evaluation of treatment adherence in patients with Behçet’s disease: its relation to disease manifestations, patients’ beliefs about medications, and quality of life. Clin Rheumatol. 2019; 38: 761-8. DOI: https://doi.org/10.1007/s10067-018-4344-3
  28. Khabbazi A, Karkon Shayan F, Ghojazadeh M, et al. Adherence to treatment in patients with Behçet’s disease. Int J Rheum Dis. 2018; 21: 2158-66. DOI: https://doi.org/10.1111/1756-185X.13109
  29. Georgopoulou S, Nel L, Sangle S, et al. O20 Physician-patient interaction and medication adherence in lupus nephritis. Rheumatology. 2018; 57: iii32-3. DOI: https://doi.org/10.1093/rheumatology/key075.202
  30. Costedoat-Chalumeau N, Houssiau F, Izmirly P, et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin Pharmacol Ther. 2018; 103: 1074-82. DOI: https://doi.org/10.1002/cpt.885
  31. Iudici M, Pantano I, Fasano S, et al. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. Lupus. 2018; 27: 265-72. DOI: https://doi.org/10.1177/0961203317717631
  32. Alsowaida N, Alrasheed M, Mayet A, Alsuwaida A, Omair MA. Medication adherence, depression and disease activity among patients with systemic lupus erythematosus. Lupus. 2018; 27: 327-32. DOI: https://doi.org/10.1177/0961203317725585
  33. Johnsen K, Jolly M, Annapureddy N. Health related quality of life in lupus: self-management-a modifiable predictor. Arthritis Rheumatol. 2017; 69: 1-3.
  34. Perel-Winkler A, Neville K, Nguyen S, et al. Low health literacy does not impact adherence to hydroxychloroquine in patients with systemic lupus. Arthritis Rheumatol. 2017; 69.
  35. Farinha F, Freitas F, Águeda A, et al. Concerns of patients with systemic lupus erythematosus and adherence to therapy - a qualitative study. Patient Prefer Adherence. 2017; 11: 1213-9. DOI: https://doi.org/10.2147/PPA.S137544
  36. Çınar M, Tekgöz E, Çınar Fİ, Yılmaz S. Reliability and validity of the turkish translation of the beliefs about medicines questionnaire (BMQ-T) in patients with Behçet’s disease. Turkish Thorac J. 2018; 19: 231-2. DOI: https://doi.org/10.5152/TurkThoracJ.2018.180108
  37. Flower C, Hambleton I, Campbell M. The effect of psychosocial and neuropsychiatric factors on medication adherence in a cohort of women with systemic lupus erythematosus. J Clin Rheumatol. 2016; 22: 411-7. DOI: https://doi.org/10.1097/RHU.0000000000000470
  38. Drenkard C, Sonia M, Gaobin B, Lim S. Depression is a risk factor for low treatment adherence in African American people with systemic lupus erythematosus. Arthritis Rheumatol. 2016; 68: 1-4550.
  39. Singh JA, Qu H, Yazdany J, et al. Barriers to medication decision making in women with lupus nephritis: a formative study using nominal group technique. J Rheumatol. 2015; 42: 1616-23. DOI: https://doi.org/10.3899/jrheum.150168
  40. Hale ED, Radvanski DC, Hassett AL. The man-in-the-moon face: a qualitative study of body image, self-image and medication use in systemic lupus erythematosus. Rheumatology (Oxford). 2015; 54: 1220-5. DOI: https://doi.org/10.1093/rheumatology/keu448
  41. Hromadkova L, Soukup T, Cermakova E, Vlcek J. Drug compliance in patients with systemic scleroderma. Clin Rheumatol. 2012; 31: 1577-83. DOI: https://doi.org/10.1007/s10067-012-2050-0
  42. Daleboudt GMN, Broadbent E, McQueen F, Kaptein AA. Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus. Arthritis Care Res. 2011; 63: 342-50. DOI: https://doi.org/10.1002/acr.20411
  43. Duvdevany I, Cohen M, Minsker-Valtzer A, Lorber M. Psychological correlates of adherence to self-care, disease activity and functioning in persons with systemic lupus erythematosus. Lupus. 2011; 20: 14-22. DOI: https://doi.org/10.1177/0961203310378667
  44. Bennett JK, Fuertes JN, Keitel M, Phillips R. The role of patient attachment and working alliance on patient adherence, satisfaction, and health-related quality of life in lupus treatment. Patient Educ Couns. 2011; 85: 53-9. DOI: https://doi.org/10.1016/j.pec.2010.08.005
  45. Chambers SA, Raine R, Rahman A, Isenberg D. Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford). 2009; 48: 266-71. DOI: https://doi.org/10.1093/rheumatology/ken479
  46. Chambers S, Raine R, Rahman A, et al. Factors influencing adherence to medications in a group of patients with systemic lupus erythematosus in Jamaica. Lupus. 2008; 17: 761-9. DOI: https://doi.org/10.1177/0961203308089404
  47. Koneru S, Kocharla L, Higgins GC, et al. Adherence to medications in systemic lupus erythematosus. J Clin Rheumatol. 2008; 14: 195-201. DOI: https://doi.org/10.1097/RHU.0b013e31817a242a
  48. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005; 32: 913-9.
  49. Vitolins MZ, Rand CS, Rapp SR, et al. Measuring adherence to behavioral and medical interventions. Control Clin Trials. 2000; 21: 188S-94S. DOI: https://doi.org/10.1016/S0197-2456(00)00077-5
  50. Garfield S, Clifford S, Eliasson L, et al. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol. 2011; 11: 149. DOI: https://doi.org/10.1186/1471-2288-11-149
  51. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS. 2002; 16: 269-77. DOI: https://doi.org/10.1097/00002030-200201250-00017
  52. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24: 67-74. DOI: https://doi.org/10.1097/00005650-198601000-00007
  53. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008; 10: 348-54.
  54. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns. 1999; 37: 113-24. DOI: https://doi.org/10.1016/S0738-3991(98)00107-4
  55. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999; 21: 1074-90; discussion 1073. DOI: https://doi.org/10.1016/S0149-2918(99)80026-5
  56. Tan X, Patel I, Chang J. Review of the four item Morisky Medication Adherence Scale (MMAS-4) and eight item Morisky Medication Adherence Scale (MMAS-8). Inov Pharm. 2014; 5(3). DOI: https://doi.org/10.24926/iip.v5i3.347
  57. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008; 10: 348-54. DOI: https://doi.org/10.1111/j.1751-7176.2008.07572.x
  58. Koneru S, Shishov M, Ware A, et al. Effectively measuring adherence to medications for systemic lupus erythematosus in a clinical setting. Arthritis Rheum. 2007; 57: 1000-6. DOI: https://doi.org/10.1002/art.22898
  59. de Klerk E, van der Heijde D, Landewé R, et al. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol. 2003; 30: 2469-75.
  60. Hughes LD, Done J, Young A. A 5 item version of the Compliance Questionnaire for Rheumatology (CQR5) successfully identifies low adherence to DMARDs. BMC Musculoskelet Disord. 2013; 14: 286. DOI: https://doi.org/10.1186/1471-2474-14-286
  61. Náfrádi L, Nakamoto K, Schulz PJ. Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. PLoS One. 2017; 12(10). DOI: https://doi.org/10.1371/journal.pone.0186458
  62. van den Bemt BJF, Gettings L, Domańska B, et al. A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv. 2019; 26: 384-92. DOI: https://doi.org/10.1080/10717544.2019.1587043
  63. Chow S-C, Chang Y-W. Statistical considerations for rare diseases drug development. J Biopharm Stat. 2019; 29: 874-86. DOI: https://doi.org/10.1080/10543406.2019.1657441
  64. Jessup RL, Osborne RH, Buchbinder R, Beauchamp A. Using co-design to develop interventions to address health literacy needs in a hospitalised population. BMC Health Serv Res. 2018; 18: 989. DOI: https://doi.org/10.1186/s12913-018-3801-7

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.